Gelonghui May 17 丨 Jincheng Pharmaceutical (300233)(300233pennpursuit3.SZ) said on the investor interaction platformpennpursuit3The company relies on years of experience in the fields of chemistry and biosynthesispennpursuit3, has built a dual synthesis research and production platform of "chemistry + biosynthesis". The company focuses on the two major directions of biocatalysis and biosynthesis, focusing on enzymatic catalysis of chiral drugs and intermediates and high value-added biosynthesis products. At present, the company's glutathione, adenosylmethionine, PQQ, 4AA, nicotine and other products have achieved industrial production and sales, forming a strong support for the company's development.